News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Receives Favorable Court Decision Regarding Generic Celebrex® Capsules; Teva Should Receive Sole Exclusivity For Generic Celebrex® Capsules



5/30/2014 9:39:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES